CN103255168B - 构建体及其应用 - Google Patents
构建体及其应用 Download PDFInfo
- Publication number
- CN103255168B CN103255168B CN201310163086.5A CN201310163086A CN103255168B CN 103255168 B CN103255168 B CN 103255168B CN 201310163086 A CN201310163086 A CN 201310163086A CN 103255168 B CN103255168 B CN 103255168B
- Authority
- CN
- China
- Prior art keywords
- construct
- animal
- cell
- nucleic acid
- present
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 210000004102 animal cell Anatomy 0.000 claims abstract description 41
- 150000007523 nucleic acids Chemical class 0.000 claims abstract description 39
- 108020004707 nucleic acids Proteins 0.000 claims abstract description 33
- 102000039446 nucleic acids Human genes 0.000 claims abstract description 33
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 25
- 239000002773 nucleotide Substances 0.000 claims abstract description 21
- 125000003729 nucleotide group Chemical group 0.000 claims abstract description 21
- 210000004027 cell Anatomy 0.000 claims description 48
- 238000000034 method Methods 0.000 claims description 42
- 239000013612 plasmid Substances 0.000 claims description 14
- 229930193140 Neomycin Natural products 0.000 claims description 4
- 229960004927 neomycin Drugs 0.000 claims description 4
- 206010059866 Drug resistance Diseases 0.000 claims description 3
- 241000700605 Viruses Species 0.000 claims description 2
- 210000004507 artificial chromosome Anatomy 0.000 claims description 2
- 239000004927 clay Substances 0.000 claims description 2
- 241001465754 Metazoa Species 0.000 abstract description 58
- 101000599951 Homo sapiens Insulin-like growth factor I Proteins 0.000 abstract description 13
- 101150088952 IGF1 gene Proteins 0.000 abstract description 13
- 102100037852 Insulin-like growth factor I Human genes 0.000 abstract description 13
- 230000012010 growth Effects 0.000 abstract description 12
- 230000006801 homologous recombination Effects 0.000 abstract description 7
- 238000002744 homologous recombination Methods 0.000 abstract description 7
- 108091028043 Nucleic acid sequence Proteins 0.000 abstract description 4
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 abstract 1
- 241000282898 Sus scrofa Species 0.000 description 26
- 230000009261 transgenic effect Effects 0.000 description 18
- 230000003321 amplification Effects 0.000 description 15
- 238000003199 nucleic acid amplification method Methods 0.000 description 15
- 210000000287 oocyte Anatomy 0.000 description 12
- 238000012797 qualification Methods 0.000 description 12
- 239000012634 fragment Substances 0.000 description 11
- 102000004169 proteins and genes Human genes 0.000 description 10
- 238000012216 screening Methods 0.000 description 9
- 238000003209 gene knockout Methods 0.000 description 8
- 210000001519 tissue Anatomy 0.000 description 8
- 238000006243 chemical reaction Methods 0.000 description 7
- 108020004414 DNA Proteins 0.000 description 6
- 206010013883 Dwarfism Diseases 0.000 description 6
- 239000003814 drug Substances 0.000 description 6
- 238000011160 research Methods 0.000 description 6
- 230000009977 dual effect Effects 0.000 description 5
- 210000004940 nucleus Anatomy 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 241000124008 Mammalia Species 0.000 description 4
- 102100022831 Somatoliberin Human genes 0.000 description 4
- 101710142969 Somatoliberin Proteins 0.000 description 4
- 238000012258 culturing Methods 0.000 description 4
- 230000008685 targeting Effects 0.000 description 4
- 102100020948 Growth hormone receptor Human genes 0.000 description 3
- 101001055320 Myxine glutinosa Insulin-like growth factor Proteins 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- 230000001413 cellular effect Effects 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 238000010367 cloning Methods 0.000 description 3
- 230000029087 digestion Effects 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 210000003754 fetus Anatomy 0.000 description 3
- 230000002068 genetic effect Effects 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 239000003550 marker Substances 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- 230000001131 transforming effect Effects 0.000 description 3
- 238000011144 upstream manufacturing Methods 0.000 description 3
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
- 102000012410 DNA Ligases Human genes 0.000 description 2
- 108010061982 DNA Ligases Proteins 0.000 description 2
- 239000000095 Growth Hormone-Releasing Hormone Substances 0.000 description 2
- 206010062767 Hypophysitis Diseases 0.000 description 2
- 229930182555 Penicillin Natural products 0.000 description 2
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 2
- 102000005157 Somatostatin Human genes 0.000 description 2
- 108010056088 Somatostatin Proteins 0.000 description 2
- 108010068542 Somatotropin Receptors Proteins 0.000 description 2
- -1 Streptomycin sulphates Chemical class 0.000 description 2
- 210000001691 amnion Anatomy 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 230000001186 cumulative effect Effects 0.000 description 2
- 238000013016 damping Methods 0.000 description 2
- 108010030074 endodeoxyribonuclease MluI Proteins 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 210000002950 fibroblast Anatomy 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- MURGITYSBWUQTI-UHFFFAOYSA-N fluorescin Chemical compound OC(=O)C1=CC=CC=C1C1C2=CC=C(O)C=C2OC2=CC(O)=CC=C21 MURGITYSBWUQTI-UHFFFAOYSA-N 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 230000004927 fusion Effects 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 210000003016 hypothalamus Anatomy 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 244000309715 mini pig Species 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 229940049954 penicillin Drugs 0.000 description 2
- 230000035790 physiological processes and functions Effects 0.000 description 2
- RXWNCPJZOCPEPQ-NVWDDTSBSA-N puromycin Chemical compound C1=CC(OC)=CC=C1C[C@H](N)C(=O)N[C@H]1[C@@H](O)[C@H](N2C3=NC=NC(=C3N=C2)N(C)C)O[C@@H]1CO RXWNCPJZOCPEPQ-NVWDDTSBSA-N 0.000 description 2
- NHXLMOGPVYXJNR-ATOGVRKGSA-N somatostatin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N1)[C@@H](C)O)NC(=O)CNC(=O)[C@H](C)N)C(O)=O)=O)[C@H](O)C)C1=CC=CC=C1 NHXLMOGPVYXJNR-ATOGVRKGSA-N 0.000 description 2
- 229960000553 somatostatin Drugs 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Natural products CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 229960005322 streptomycin Drugs 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 210000004291 uterus Anatomy 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 102000002322 Egg Proteins Human genes 0.000 description 1
- 108010000912 Egg Proteins Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- YQYJSBFKSSDGFO-UHFFFAOYSA-N Epihygromycin Natural products OC1C(O)C(C(=O)C)OC1OC(C(=C1)O)=CC=C1C=C(C)C(=O)NC1C(O)C(O)C2OCOC2C1O YQYJSBFKSSDGFO-UHFFFAOYSA-N 0.000 description 1
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 1
- 102000004144 Green Fluorescent Proteins Human genes 0.000 description 1
- 102000018997 Growth Hormone Human genes 0.000 description 1
- 108010051696 Growth Hormone Proteins 0.000 description 1
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 1
- 102000003960 Ligases Human genes 0.000 description 1
- 108090000364 Ligases Proteins 0.000 description 1
- 108010047357 Luminescent Proteins Proteins 0.000 description 1
- 102000006830 Luminescent Proteins Human genes 0.000 description 1
- 101100190468 Mus musculus Pigs gene Proteins 0.000 description 1
- 241001045988 Neogene Species 0.000 description 1
- 208000025174 PANDAS Diseases 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 208000021155 Paediatric autoimmune neuropsychiatric disorders associated with streptococcal infection Diseases 0.000 description 1
- 240000000220 Panda oleosa Species 0.000 description 1
- 235000016496 Panda oleosa Nutrition 0.000 description 1
- 108010076504 Protein Sorting Signals Proteins 0.000 description 1
- 108091028664 Ribonucleotide Proteins 0.000 description 1
- 102000013275 Somatomedins Human genes 0.000 description 1
- 238000002105 Southern blotting Methods 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 101100452304 Sus scrofa IGF1 gene Proteins 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 238000000246 agarose gel electrophoresis Methods 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 239000012930 cell culture fluid Substances 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000004737 colorimetric analysis Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 239000005547 deoxyribonucleotide Substances 0.000 description 1
- 125000002637 deoxyribonucleotide group Chemical group 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 230000003328 fibroblastic effect Effects 0.000 description 1
- 238000007667 floating Methods 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- 239000005090 green fluorescent protein Substances 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000003547 immunosorbent Substances 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 230000007102 metabolic function Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 101150091879 neo gene Proteins 0.000 description 1
- 210000000607 neurosecretory system Anatomy 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 210000004681 ovum Anatomy 0.000 description 1
- 230000008288 physiological mechanism Effects 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 229950010131 puromycin Drugs 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 239000003488 releasing hormone Substances 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 239000002336 ribonucleotide Substances 0.000 description 1
- 125000002652 ribonucleotide group Chemical group 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 238000007447 staining method Methods 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 238000010361 transduction Methods 0.000 description 1
- 230000026683 transduction Effects 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 238000010200 validation analysis Methods 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 239000009654 wuzhi Substances 0.000 description 1
Abstract
Description
组分 | 质量/体积 |
DNA | 50ng |
dNTP | 1.6μl |
FP(上游引物) | 0.4μl |
RP(下游引物) | 0.4μl |
5x phusion缓冲液 | 4μl |
phusion | 0.1μl |
补H2O至总体积 | 20μl |
组分 | 质量/体积 |
DNA | 20-50 ng |
dNTP | 1.6 μl |
FP(上游引物) | 0.3 μl |
RP(下游引物) | 0.3 μl |
5x phusion缓冲液 | 3 μl |
phusion | 0.1 μl |
补H2O至总体积 | 15 μl |
Claims (7)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201310163086.5A CN103255168B (zh) | 2013-05-06 | 2013-05-06 | 构建体及其应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201310163086.5A CN103255168B (zh) | 2013-05-06 | 2013-05-06 | 构建体及其应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN103255168A CN103255168A (zh) | 2013-08-21 |
CN103255168B true CN103255168B (zh) | 2015-07-01 |
Family
ID=48959378
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201310163086.5A Active CN103255168B (zh) | 2013-05-06 | 2013-05-06 | 构建体及其应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN103255168B (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR3056991A1 (fr) * | 2016-10-03 | 2018-04-06 | C.A.L.-Laboratoire De Biologie Veterinaire | Methode et kit de detection, de discrimination et identification d'especes de borrelies presentes dans un echantillon d'origine humaine ou animale |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106318965B (zh) * | 2015-06-26 | 2019-05-07 | 深圳华大生命科学研究院 | 人工半合成染色体的整合方法及含有完整合成染色体的微生物 |
CN113278625A (zh) * | 2021-03-12 | 2021-08-20 | 新疆农垦科学院 | 用于培育特异igf1转基因绵羊的基因序列及其鉴定引物和鉴定方法 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003031629A1 (en) * | 2001-10-09 | 2003-04-17 | Copyrat Pty Ltd | Methods of preparing a targeting vector and uses thereof |
CN1970749A (zh) * | 2005-11-25 | 2007-05-30 | 上海杰隆生物工程股份有限公司 | 一种制备朊蛋白基因敲除家畜的方法 |
CN101955961A (zh) * | 2009-07-03 | 2011-01-26 | 北京济福霖生物技术有限公司 | 一种基因敲除打靶载体及其应用 |
-
2013
- 2013-05-06 CN CN201310163086.5A patent/CN103255168B/zh active Active
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003031629A1 (en) * | 2001-10-09 | 2003-04-17 | Copyrat Pty Ltd | Methods of preparing a targeting vector and uses thereof |
CN1970749A (zh) * | 2005-11-25 | 2007-05-30 | 上海杰隆生物工程股份有限公司 | 一种制备朊蛋白基因敲除家畜的方法 |
CN101955961A (zh) * | 2009-07-03 | 2011-01-26 | 北京济福霖生物技术有限公司 | 一种基因敲除打靶载体及其应用 |
Non-Patent Citations (5)
Title |
---|
Homologous recombination in hybridomacells: dependence on time and fragment length.;Shulman M.J.等;《Mol Cell biol》;19921231;2919-2923 * |
IGF轴与胎儿生长调节;贲晓明等;《中国当代儿科杂志》;20000630;第2卷(第3期);237-240 * |
Mice carring mull mutations of the gene encoding IGF-I and type-II IGF recptor.;Liu JP.等;《Cell》;19931231;第75卷(第1期);摘要和图1 * |
人胰岛素样生长因子1基因的克隆、表达及产物纯化与检定;吴岚晓;《中国优秀硕士学位论文全文数据库》;20020615;E059-97 * |
基因敲除技术及其应用;黄敏;《广东轻工职业技术学院学报》;20091231;第8卷(第4期);11-14 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR3056991A1 (fr) * | 2016-10-03 | 2018-04-06 | C.A.L.-Laboratoire De Biologie Veterinaire | Methode et kit de detection, de discrimination et identification d'especes de borrelies presentes dans un echantillon d'origine humaine ou animale |
WO2018065367A1 (fr) * | 2016-10-03 | 2018-04-12 | C.A.L.-Laboratoire De Biologie Vétérinaire | Methode et kit de detection, de discrimination et identification d'especes de borrelies presentes dans un echantillon d'origine humaine ou animale |
Also Published As
Publication number | Publication date |
---|---|
CN103255168A (zh) | 2013-08-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Wagner et al. | Tsg101 is essential for cell growth, proliferation, and cell survival of embryonic and adult tissues | |
CN109943564B (zh) | Amh基因定点敲入2A-Cre的杂合子小鼠模型构建方法及其应用 | |
CN111154763B (zh) | 长链非编码RNA lncMGPF在调控猪肌肉发育功能中的应用 | |
CN101760473B (zh) | 一种定点删除转基因细胞中的外源基因的方法 | |
CN103255168B (zh) | 构建体及其应用 | |
Carvalho et al. | Production of transgenic cattle by somatic cell nuclear transfer (SCNT) with the human granulocyte colony-stimulation factor (hG-CSF) | |
CN112057611A (zh) | 非洲猪瘟病毒e120r蛋白作为免疫抑制剂的应用及免疫抑制位点敲除毒株的构建 | |
Li et al. | HMEJ-mediated site-specific integration of a myostatin inhibitor increases skeletal muscle mass in porcine | |
CN102080101A (zh) | 一种定点整合外源基因的方法 | |
CN102747102B (zh) | 一种hsa乳腺特异性表达载体及其构建的重组细胞 | |
CN1869217B (zh) | 以腺病毒为载体乳腺表达生产转基因蛋白药物的方法 | |
CN107988257B (zh) | 基于供体细胞dna甲基化水平的修饰提高山羊克隆效率的载体、细胞及方法 | |
CN102807993B (zh) | 一种骨骼肌特异性的靶向Myostatin基因的miRNA表达载体及重组细胞 | |
CN104232643A (zh) | RNAi干扰片段、干扰载体、制备方法及其应用 | |
CN101519664B (zh) | 一种重组腺病毒载体制备转基因动物的方法 | |
CN103484497A (zh) | 利用家兔乳腺反应器平台生产重组人第七凝血因子的方法 | |
CN114107176A (zh) | 一种稳定表达非洲猪瘟CD2v蛋白的CHO细胞系及其构建方法和应用 | |
CN104450781B (zh) | 一种过表达ciapin1蛋白的细胞系及其制备方法和应用 | |
Gao et al. | Transfection and expression of exogenous gene in laying hens oviduct in vitro and in vivo | |
CN101851638A (zh) | 一种包含Ipr1巨噬细胞异性表达载体的牛胎儿成纤维细胞 | |
CN106177906B (zh) | Ddb1蛋白的应用 | |
CN103145824B (zh) | 一种突变型隐色素基因1和突变型隐色素基因1的转基因猪 | |
Chen et al. | Construction of multiple shRNAs expression vector that inhibits FUT1 gene expression and production of the transgenic SCNT embryos in vitro | |
Lin et al. | Construction of mammary gland specific expression plasmid pIN and its expression in vitro and in vivo | |
Zakharova et al. | Transcription and mRNA splicing of the human lactoferrin gene controlled by the regulatory region of the bovine α S1 casein gene in the mammary gland of transgenic mice and in mouse embryonic stem cells |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
CP03 | Change of name, title or address | ||
CP03 | Change of name, title or address |
Address after: 518083 Yantian District, Yantian District, Shenzhen, Guangdong. Patentee after: BGI SHENZHEN Address before: 518083 comprehensive building, Beishan Industrial Zone, Yantian District, Shenzhen, Guangdong Patentee before: BGI SHENZHEN |
|
PE01 | Entry into force of the registration of the contract for pledge of patent right | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: Polynucleotide constructs and uses thereof Effective date of registration: 20180917 Granted publication date: 20150701 Pledgee: China Minsheng Banking Corp Shenzhen branch Pledgor: BGI SHENZHEN Registration number: 2018440020059 |
|
PC01 | Cancellation of the registration of the contract for pledge of patent right | ||
PC01 | Cancellation of the registration of the contract for pledge of patent right |
Date of cancellation: 20200410 Granted publication date: 20150701 Pledgee: China Minsheng Banking Corp Shenzhen branch Pledgor: BGI SHENZHEN Registration number: 2018440020059 |
|
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20211223 Address after: 518083 8th floor, building 11, Beishan Industrial Zone, 146 Beishan Road, Yangang community, Yantian street, Yantian District, Shenzhen, Guangdong Patentee after: BGI SHENZHEN Co.,Ltd. Address before: 518083 Yantian District, Yantian District, Shenzhen, Guangdong. Patentee before: BGI SHENZHEN |
|
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20230605 Address after: No.7 Pengfei Road, Dapeng Office, Dapeng New Area, Shenzhen City, Guangdong Province, 518000 Patentee after: Shenzhen Huada Sansheng Garden Technology Co.,Ltd. Address before: 518083 8th floor, building 11, Beishan Industrial Zone, 146 Beishan Road, Yangang community, Yantian street, Yantian District, Shenzhen, Guangdong Patentee before: BGI SHENZHEN Co.,Ltd. |